EQS-Adhoc: IGEA ANNOUNCES ANNUAL GENERAL MEETING RESOLUTIONS
IGEA ANNOUNCES ANNUAL GENERAL MEETING RESOLUTIONS
Hoofddorp, the Netherlands, 9 July 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that its shareholders followed the recommendations of the company. The minutes of the general meeting is available athttps://www.igeapharma.nl/category/information-for-shareholders/
About IGEA IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. Health-tech products are exclusively preventative. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in 2021. Non-bound copper is an expected Alzheimer's and diabetes type II associated biomarker. Controlling non-bound copper can contribute to reduce the risk of Alzheimer's and diabetes type II. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies. Med-tech products focuses on selected solutions and specialties, among which dry aerosol generators for air and inanimate environmental surfaces sanitization and sterilization and air purification devices.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
Disclaimer This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development, or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.
Additional features:File: Igea Pharma_press release 09072021End of ad hoc announcement Language: English Company: IGEA Pharma N.V. Siriusdreef 17 2123 WT Hoofddorp
Netherlands Phone: +31 23 568 9494 E-mail: email@example.com Internet: www.igeapharma.nl ISIN: NL0012768675 Listed: Regulated Unofficial Market in Frankfurt; BX Berne eXchange; SIX Swiss Exchange EQS News ID: 1217471 ? End of Announcement EQS Group News Service